Bluejay Diagnostics (NASDAQ:BJDX) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Bluejay Diagnostics (NASDAQ:BJDX) from a hold rating to a sell rating in a research note released on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Bluejay Diagnostics has an average rating of “Sell”.

Bluejay Diagnostics Trading Down 1.0%

BJDX stock opened at $0.90 on Friday. Bluejay Diagnostics has a 12-month low of $0.83 and a 12-month high of $16.68. The business’s 50-day moving average is $1.34 and its 200 day moving average is $2.04. The stock has a market cap of $4.02 million, a price-to-earnings ratio of -0.13 and a beta of 0.89.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its earnings results on Wednesday, August 12th. The company reported ($1.12) EPS for the quarter, beating analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Insider Transactions at Bluejay Diagnostics

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt sold 34,938 shares of the stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the completion of the sale, the insider owned 92,055 shares in the company, valued at approximately $128,877. This represents a 27.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. Institutional investors and hedge funds own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.